WMDH yields 2000000.00% · ABBV yields 3.06%● Live data
📍 WMDH pulled ahead of the other in Year 1
Combined, WMDH + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WMDH + ABBV for your $10,000?
WMD Holdings Group, Inc. engages in the development and deployment of turnkey solutions for financial and payment processing, prepaid services, telecommunications, and interactive broadcasting networks in the United States. The company offers NAVITOUCH, an interactive broadcast network system that enables worldwide broadcasting of interactive content and advertising to various touch screen monitors; local and long-distance telephone services; and financial, payment, and communication services through its point of sale terminals, which facilitate the recharge and distribution of a multitude of pre-paid offerings, including pre-paid debit cards, pre-paid wireless distribution, and pre-paid long distance. It also provides debit card solutions; closed loop stored value and gift card programs; check cashing and bill payment services; cell phone sales; shipping; and money transfers. In addition, WMD Holdings offers payday advances and loans to consumers requiring emergency funding, short term bridge loans, and advances on payroll. It primarily distributes its solutions through a combination of company owned and operated locations, online, and other independent sales organizations to the financial, payment processing, telecommunications, and advertising industries. The company was founded in 2001 and is based in Huntington Beach, California.
Full WMDH Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.